ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 30 Sep 2021
Last Updated on 30 Sep 2021
A- A+
Guidance Recommendation

The Ministry of Health’s MTAC has not recommended subsidising photodynamic therapy in the treatment of non-melanoma skin tumours including actinic keratosis, basal cell carcinoma, and squamous cell carcinoma in situ (or Bowen’s disease).

Subsidy status

Photodynamic therapy is not recommended for subsidy in patients with the abovementioned indications.


Photodynamic therapy for treating non-melanoma skin tumours